SG Americas Securities LLC Raises Stock Holdings in Organogenesis $ORGO

SG Americas Securities LLC boosted its holdings in shares of Organogenesis (NASDAQ:ORGO) by 39.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 790,766 shares of the company’s stock after purchasing an additional 225,265 shares during the quarter. SG Americas Securities LLC owned about 0.61% of Organogenesis worth $1,874,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. First Light Asset Management LLC lifted its stake in shares of Organogenesis by 10.6% in the 3rd quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock valued at $31,641,000 after purchasing an additional 720,748 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Organogenesis by 14.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after purchasing an additional 680,392 shares during the last quarter. Deutsche Bank AG increased its position in shares of Organogenesis by 0.4% during the 4th quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after purchasing an additional 13,301 shares during the last quarter. Geode Capital Management LLC raised its holdings in Organogenesis by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock valued at $9,259,000 after buying an additional 62,346 shares during the period. Finally, Norges Bank purchased a new stake in Organogenesis during the 4th quarter valued at $5,686,000. 49.57% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on ORGO shares. Wall Street Zen raised shares of Organogenesis from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Truist Financial assumed coverage on shares of Organogenesis in a research note on Thursday, May 28th. They issued a “hold” rating and a $3.00 target price on the stock. UBS Group set a $3.00 target price on shares of Organogenesis in a report on Thursday, May 28th. BTIG Research lowered shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.75.

Organogenesis Price Performance

Shares of ORGO stock opened at $2.36 on Friday. The company has a market capitalization of $303.68 million, a P/E ratio of -12.42 and a beta of 1.33. The company’s 50-day simple moving average is $2.45 and its two-hundred day simple moving average is $3.19. Organogenesis has a one year low of $2.04 and a one year high of $7.08. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.53 and a quick ratio of 3.16.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%. The company had revenue of $37.23 million for the quarter, compared to the consensus estimate of $43.26 million.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.